A neck node with no obvious primary
A 57-year-old man presents with a 3 cm firm left level II lymph node. He has no oral symptoms, no hoarseness, no dysphagia, and no skin lesions. Examination of the oral cavity, oropharynx, and nasopharynx is unremarkable. FNA shows squamous cell carcinoma; p16 immunohistochemistry is strongly positive in the tumor cells. CT shows an enlarged node but no obvious primary. He asks what p16 positivity means and whether he needs a full panendoscopy.
1. What does strong p16 positivity in a neck node indicate, and how should it direct the search for a primary?
Read the worked answer
Strong, diffuse p16 positivity in a squamous cell carcinoma of the head and neck is a surrogate for HPV-associated (largely HPV-16) oropharyngeal carcinoma, most often arising in the tonsil or base of tongue. In a patient with a neck node and no obvious primary, p16 positivity should direct the workup to the oropharynx, including careful examination and imaging (and often tonsillectomy or directed biopsies) of the tonsils and base of tongue.
Judgment point: p16 positivity is not just a prognostic marker - it is a localizing clue. It narrows the search from a broad panendoscopy to the oropharynx and changes expected prognosis (HPV-associated cancers have better outcomes).
2. How does the p16 result influence prognosis and treatment discussion compared with a p16-negative node?
Read the worked answer
HPV-associated/p16-positive oropharyngeal SCC has substantially better prognosis (higher survival, better response to therapy) than p16-negative disease. This supports:
- Discussion of de-escalated treatment approaches in appropriate settings, though de-escalation remains protocol-dependent and should not be assumed outside a trial or guideline.
- Different staging expectations (HPV-associated oropharyngeal cancer has its own staging system).
It does not mean no treatment; it changes risk stratification and the framing of the conversation. The p16-negative scenario would carry a worse prognosis and a broader search for a primary, including lung and other mucosal sites.